Abstract: Adenosine receptor (e.g., A2A and/or A1 receptor) antagonist compounds and compositions including the adenosine receptor antagonist compounds are disclosed. Methods of using the compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and/or A1 receptor in a biological system are also disclosed. The compounds and compositions find use in various therapeutic applications including the treatment of cancer and in immuno-oncology. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson's disease.

Abstract: An electrode current collector includes an alloy containing Ni and Cu, and CeO2, wherein a porosity of the electrode current collector is 25 to 80%. A method of manufacturing an electrode current collector includes preparing a mixed powder by mixing an alloy powder containing Ni and Cu with CeO2, manufacturing a molded body by applying a pressure to the mixed powder, and subjecting the molded body to a heat treatment at 450 to 1,000° C.

Abstract: Provided are an air electrode composite, a method of manufacturing the same, and an electrochemical cell including the same. Specifically, an air electrode composite in which electron conductive nanoparticles are uniformly distributed on the surface of an oxygen ion conductive porous structure, a method of manufacturing the same, and an electrochemical cell including the same are provided.

Abstract: According to an embodiment of the present disclosure, there is a wearable electronic device, comprising: a first sensor configured to sense a movement of the electronic device; a second sensor configured to sense a biological signal for a user wearing the electronic device; and a processor configured to compute a movement value of the electronic device using the first sensor, to detect a resting state when the movement value lasts within a predetermined first threshold range during a first time period, and to configure biological information of the user based on a biological signal measured after detection of the resting state.

Abstract: The present invention includes: a porous structure containing an oxygen ion conductive material; and a coating layer disposed on the porous structure and containing an electronically conductive material, in which a content of the oxygen ion conductive material is greater than that of the electronically conductive material, and the coating layer is uniformly formed to a thickness of 20 nm or less.

Abstract: Disclosed are methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, disorder of bile acid homeostasis, or organ fibrosis, which includes administering to a subject a therapeutically effective amount of a pharmaceutical composition containing an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.

Abstract: The present disclosure provides autotaxin (ATX) inhibitor compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for inhibiting ATX. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.

Abstract: The present disclosure provides autotaxin (ATX) inhibitor compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for inhibiting ATX. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.

Abstract: The present invention provides methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, or organ fibrosis, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.

Abstract: An organic light emitting diode display device includes a substrate having a sub-pixel and a transparent region, a counter substrate facing into the substrate, and a light emitting diode and a light controlling element between the substrate and the counter substrate, the light controlling element transmitting or shielding a light. The light emitting diode overlaps the sub-pixel, and the light controlling element overlaps the transparent region.

Abstract: The present disclosure provides adenosine receptor (e.g., A2A and/or A1 receptor) antagonist compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and/or A1 receptor in a biological system. The compounds and compositions find use in various therapeutic applications including the treatment of cancer and in immuno-oncology. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson’s disease.

Abstract: A vehicle running mode control method may include detecting, by a mode controller, a mode switching from an electric vehicle mode (EV mode) to a hybrid electric vehicle mode (HEV mode) while a vehicle runs; and performing a continuously variable transmission (CVT) cooperative mode switching control in which a drive motor is connected to an engine by engaging a clutch by operating the CVT.

Abstract: In a cruise control method and a cruise control apparatus for a manual transmission vehicle, upon receiving a signal from an input device to start a cruise mode, a cruise control controller calculates an optimal gear stage for satisfying a target cruise traveling speed according to a traveling state of a vehicle, and a display device displays the calculated optimal gear stage to the driver to induce the driver to shift to the optimal gear stage. In addition, whether the gear stage by the driver's operation has matched the optimal gear stage may be determined within a predetermined time to determine whether a cruise control continues according to the determination result, thereby eliminating the driver's inconvenience due to frequent cancellation of the cruise mode.

Abstract: A system for preventing abnormal acceleration of a vehicle includes a device configured such that in a state in which the vehicle is stopped while the vehicle is turned on, the device is configured to determine whether abnormal acceleration prevention is necessary based on a final destination or a current position of the vehicle before the vehicle is turned off to thereby limit a vehicle speed. The system and a method for preventing abnormal operation of the vehicle can prevent a vehicle accident due to the abnormal acceleration caused by misoperation by a driver, such as misoperation of an accelerator pedal of the vehicle.

Abstract: A system for controlling a remote smart parking assist (RSPA) system is provided. The system includes an engine control unit (ECU) that is configured to operate an engine and an RSPA controller that is configured to receive vehicle state information from the ECU regarding whether or not a vehicle system error occurs and, if an error occurs, whether or not the error is an error in which a vehicle is possible to be driven. The RSPA controller is further configured to transmit torque request information to the ECU when the vehicle system error is an error in which the vehicle is possible to be driven.

Abstract: The present disclosure provides phosphodiesterase 5 (PDE-5) and/or phosphodiesterase 6 (PDE-6) inhibitor compounds and compositions including said compounds. In some embodiments, said compounds are nitrogen oxide (NO) donating PDE-5 and/or -6 inhibitor compounds that include a nitrogen oxide-containing donor substituent attached to a benzenesulfonamide group. The compounds can provide dual functionality for increasing protein kinase G (PKG) activity by inhibiting PDE-5 and PDE-6, and/or stimulating guanylate cyclase (sGC) via donation of nitrogen oxide (NO) from the donor substituent of the compound. The present disclosure also provides methods of using said compounds and compositions for inhibiting PDE-5 and/or -6 and increasing activity of protein kinase G (PKG). The compounds and compositions find use in therapeutic applications including in the treatment of a variety of eye diseases.

Abstract: A cruise operation fuel efficiency improvement control method, the method may include detecting, by an engine control unit, a cruise Resume request during a coasting running state of a vehicle; controlling a NCC Cruise Control which performs a cruise torque control of the vehicle after performing a control of an Electronic Stability Control (ESC) which sets a vehicle speed to a cruise target speed followed by a control of a transmission control unit, when the coasting running is recognized as a Neutral Control Coasting (NCC); and controlling a SSC Cruise Control which performs the cruise torque control of the vehicle after performing the control of the Electronic Stability Control (ESC) which sets the vehicle speed to the cruise target speed followed by the control of the transmission control unit in a driving state of an engine, when the coasting running is recognized as a Start Stop Control (SSC).

Abstract: The present disclosure provides autotaxin (ATX) inhibitor compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for inhibiting ATX. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.

Abstract: A foldable container enables the entire height of a folded state thereof to be one fifth of the entire height of the state of being folded, such that the height of an international standard container can be satisfied even though empty containers are stacked in five stages. To this end, the hexagonal foldable container can include an upper panel part and a lower panel part respectively forming the upper surface and lower surface thereof; a left panel part and a right panel part respectively forming the left surface and right surface thereof, and respectively folded; a front panel part and a rear panel part respectively forming the front surface and rear surface thereof; and a fixing bar provided at the outer surface of the rear panel part.

Abstract: The present invention relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.